Cost-utility analysis of Lopinavir/Ritonavir versus Atazanavir + Ritonavir administered as first-line therapy for the treatment of HIV infection in Italy: from randomised trial to real world
29 Aprile 2015. Categoria: Other
Foglia, E., Bonfanti, P., Rizzardini, G., Bonizzoni, E., Restelli, U., Ricci, E., Porazzi, E., Scolari, F., Croce, D., (2013), “Cost-utility analysis of Lopinavir/Ritonavir versus Atazanavir + Ritonavir administered as first-line therapy for the treatment of HIV infection in Italy: from randomised trial to real world”, PLoS ONE, 2013, 8(2): e57777.
Emanuele Porazzi
Socio Aggregato junior dal 2014
